Home > Resources > Company Profiles > Pain Therapeutics, Incorporated

Pain Therapeutics, Incorporated (PTIE)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Remi Barbier , Founder/CEO/Chairman of the Board/Director/President
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Remi Barbier, Founder/CEO/Chairman of the Board/Director/President

2211 Bridgepointe Parkway

Suite 500

San Mateo, CA 94404

US Map it

Phone: (650) 624-8200

Fax: (650) 624-8222

www.paintrials.com



Overview

A biopharmaceutical company that develops novel drugs. It has four drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma.

Employees

Number of Employees: 47
Revenue per Employee: $1,421,098

Top Executives

Peter S. Roddy, CFO/Vice President
Dr. Grant L. Schoenhard, Ph.D., Chief Scientific Officer
Dr. Nadav Friedmann, Ph.D., M.D., COO/Chief Medical Officer/Director

Board of Directors

Dr. Robert Z. Gussin, Ph.D., Director
Sanford R. Robertson, Director
Peter S. Roddy, CFO/Vice President

Michael J. O'Donnell, Esq., Director/Secretary
Dr. Grant L. Schoenhard, Ph.D., Chief Scientific Officer
Dr. Nadav Friedmann, Ph.D., M.D., COO/Chief Medical Officer/Director

Financials

Quarterly
Annual

Income Statement 07/2008 05/2008 02/2008 11/2007
Sales -117 K. -117 K. NA -13.18 Mil.
Gross Operating Profit 10.66 Mil. 14.76 Mil. 14.06 Mil. 28.99 Mil.
Operating Income before D & A (EBITDA) -2.45 Mil. 453 K. -1.64 Mil. 13.71 Mil.
Total Income Before Interest Expenses (EBIT) -1.02 Mil. 2.57 Mil. 1.13 Mil. 3.17 Mil.
Total Net Income -1.02 Mil. 2.57 Mil. 1.13 Mil. 3.17 Mil.
Basic EPS, Total -0.02 0.06 0.03 0.07
Diluted EPS, Total -0.02 0.06 0.02 0.07

BALANCE STATEMENT 07/2008 05/2008 02/2008 11/2007
Cash and Equivalents 125.42 Mil. 130.81 Mil. 205.07 Mil. 40.81 Mil.
Total Assets 177.1 Mil. 190.36 Mil. 205.37 Mil. 206.41 Mil.
Total Liabilities 19.85 Mil. 20.71 Mil. 207.62 Mil. 34.76 Mil.
Total Capitalization 83.39 Mil. 92.32 Mil. 103.91 Mil. 99.05 Mil.

Cash Flow 07/2008 05/2008 02/2008 11/2007
Net Cash From Continuing Operations -1.91 Mil. 1.61 Mil. NA 4.96 Mil.
Net Cash From Investing Activities 65.96 Mil. 58.64 Mil. NA 22.09 Mil.
Net Cash From Financing Activities -25.19 Mil. -16.01 Mil. NA -2.63 Mil.
Net Change in Cash & Cash Equivalents 38.86 Mil. 44.24 Mil. NA 24.43 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales NA 25.86 Mil. -368 K. -383 K.
Gross Operating Profit 65.98 Mil. 28.06 Mil. 5.45 Mil. 383 K.
Operating Income before D & A (EBITDA) 10.17 Mil. -26.41 Mil. -32.35 Mil. -38.58 Mil.
Total Income Before Interest Expenses (EBIT) 20.3 Mil. 9.12 Mil. -30.67 Mil. -37.78 Mil.
Total Net Income 20.3 Mil. 6.19 Mil. -30.67 Mil. -37.78 Mil.
Basic EPS, Total 0.46 0.14 -0.7 -1.01
Diluted EPS, Total 0.44 0.14 -0.7 -1.01

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents 205.07 Mil. 16.39 Mil. 95.65 Mil. 1.38 Mil.
Total Assets 205.37 Mil. 207.11 Mil. 214.16 Mil. 99.66 Mil.
Total Liabilities 207.62 Mil. 36.65 Mil. 32.35 Mil. 7.8 Mil.
Total Capitalization 103.91 Mil. 77.92 Mil. 63.36 Mil. 93.4 Mil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations NA -11.83 Mil. 113.23 Mil. -32.57 Mil.
Net Cash From Investing Activities NA -69.14 Mil. -19.28 Mil. -32.88 Mil.
Net Cash From Financing Activities NA 1.7 Mil. 321 K. 54.8 Mil.
Net Change in Cash & Cash Equivalents NA -79.26 Mil. 94.27 Mil. -10.65 Mil.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Ligand Pharmaceuticals, Incorporated Class B
400.82 Mil.
Durect Corporation
409.53 Mil.
Cardiome Pharma Corporation
416.1 Mil.
Biodel, Incorporated
362.25 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented